Survey with $100 giveaway: what do you prescribe when metformin fails?

Question Title

* 2. How likely are you to refer to the RACGP’s Australian type 2 diabetes management algorithm to assist you with prescribing decisions?

Very likely

Somewhat likely

Not at all likely

Question Title

* 3. Thinking about your 2nd and 3rd line prescribing practices for T2D, which of these statements is true for you? (Answer YES or NO for each option)

	Yes	No
I tend to favour an SGLT2i for suitable patients	I tend to favour an SGLT2i for suitable patients Yes	I tend to favour an SGLT2i for suitable patients No
I tend to favour a GLP-1RA for suitable patients	I tend to favour a GLP-1RA for suitable patients Yes	I tend to favour a GLP-1RA for suitable patients No
I am confident prescribing an SGLT2i or GLP-1RA	I am confident prescribing an SGLT2i or GLP-1RA Yes	I am confident prescribing an SGLT2i or GLP-1RA No
I am more likely to prescribe insulin	I am more likely to prescribe insulin Yes	I am more likely to prescribe insulin No
I am more comfortable with the older DPP4-i or SU classes	I am more comfortable with the older DPP4-i or SU classes Yes	I am more comfortable with the older DPP4-i or SU classes No

Question Title

* 4. Would you say you have an adequate understanding of the GLP-1RA mechanism of action? (Answer on a scale of 1-5 with 1 being low understanding and 5 being high understanding

Clear

i We adjusted the number you entered based on the slider’s scale.

Question Title

* 5. Which of the following combinations do you consider to be clinically advantageous? (Answer YES or NO for each option)

	Yes	No
SGLT2i with a GLP-1RA	SGLT2i with a GLP-1RA Yes	SGLT2i with a GLP-1RA No
GLP-1RA with insulin	GLP-1RA with insulin Yes	GLP-1RA with insulin No
GLP-1RA with a DPP-4i	GLP-1RA with a DPP-4i Yes	GLP-1RA with a DPP-4i No

Question Title

* 6. Which of the following combinations are you currently prescribing? (Answer YES or NO for each option)

	Yes	No
SGLT2i with a GLP-1RA	SGLT2i with a GLP-1RA Yes	SGLT2i with a GLP-1RA No
GLP-1RA with insulin	GLP-1RA with insulin Yes	GLP-1RA with insulin No
GLP-1RA with a DPP-4i	GLP-1RA with a DPP-4i Yes	GLP-1RA with a DPP-4i No
Metformin with a SU	Metformin with a SU Yes	Metformin with a SU No

Question Title

* 7. What, if any, are your biggest challenges for prescribing a GLP-1RA? (Answer YES or NO for each option)

	Yes	No
Unfamiliarity with prescribing this class	Unfamiliarity with prescribing this class Yes	Unfamiliarity with prescribing this class No
Gastrointestinal side effects	Gastrointestinal side effects Yes	Gastrointestinal side effects No
Hypoglycaemia	Hypoglycaemia Yes	Hypoglycaemia No
PBS restrictions for this class	PBS restrictions for this class Yes	PBS restrictions for this class No
Time/resources required for initiation of injectable	Time/resources required for initiation of injectable Yes	Time/resources required for initiation of injectable No
Patient aversion to injectables	Patient aversion to injectables Yes	Patient aversion to injectables No
Patient concern about additional cost	Patient concern about additional cost Yes	Patient concern about additional cost No
Patient concern about multiple therapies	Patient concern about multiple therapies Yes	Patient concern about multiple therapies No
Patient concept of injectables being end stage	Patient concept of injectables being end stage Yes	Patient concept of injectables being end stage No

Question Title

* 8. What do you think are the main benefits of a GLP-1RA? (Answer YES or NO for each option)

	Yes	No
Efficacy	Efficacy Yes	Efficacy No
Weight loss	Weight loss Yes	Weight loss No
Cardiovascular safety	Cardiovascular safety Yes	Cardiovascular safety No
Once-weekly administration	Once-weekly administration Yes	Once-weekly administration No
Side effect profile	Side effect profile Yes	Side effect profile No
Patient compliance	Patient compliance Yes	Patient compliance No

Question Title

* 9. Of the following GLP-1RAs which are you most likely to prescribe for a suitable patient?

Dulaglutide (Trulicity®)

Exenatide (Byetta®)

Exenatide (Bydureon®)

Semaglutide (Ozempic®)

Question Title

* 10. What type of support would be beneficial to assist you with initiation of a GLP-1RA? (Answer YES or NO for each option)

	Yes	No
Access/sponsorship to a diabetes educator	Access/sponsorship to a diabetes educator Yes	Access/sponsorship to a diabetes educator No
Access to faster referral pathways	Access to faster referral pathways Yes	Access to faster referral pathways No
Nurse practitioner on site	Nurse practitioner on site Yes	Nurse practitioner on site No
Nurse practitioner virtually	Nurse practitioner virtually Yes	Nurse practitioner virtually No
CPD accredited education	CPD accredited education Yes	CPD accredited education No
Drug samples	Drug samples Yes	Drug samples No
Pharma company meetings	Pharma company meetings Yes	Pharma company meetings No

Question Title

* 11. In general, what do you find most challenging about treating and managing patients with diabetes? (Choose three of the following)

Understanding which medication to use

Navigating T2D guidelines

Patient non-compliance

Access to specialist/nurse/educator

Telehealth consultation limitations

Patient comorbidities

Patient load/consultation time constraints

Survey with $100 giveaway: what do you prescribe when metformin fails?

Question Title

* 1. Where is your clinic based?

Question Title

* 2. How likely are you to refer to the RACGP’s Australian type 2 diabetes management algorithm to assist you with prescribing decisions?

Question Title

* 3. Thinking about your 2nd and 3rd line prescribing practices for T2D, which of these statements is true for you? (Answer YES or NO for each option)

Question Title

* 4. Would you say you have an adequate understanding of the GLP-1RA mechanism of action? (Answer on a scale of 1-5 with 1 being low understanding and 5 being high understanding

Question Title

* 5. Which of the following combinations do you consider to be clinically advantageous? (Answer YES or NO for each option)

Question Title

* 6. Which of the following combinations are you currently prescribing? (Answer YES or NO for each option)

Question Title

* 7. What, if any, are your biggest challenges for prescribing a GLP-1RA? (Answer YES or NO for each option)

Question Title

* 8. What do you think are the main benefits of a GLP-1RA? (Answer YES or NO for each option)

Question Title

* 9. Of the following GLP-1RAs which are you most likely to prescribe for a suitable patient?

Question Title

* 10. What type of support would be beneficial to assist you with initiation of a GLP-1RA? (Answer YES or NO for each option)

Question Title

* 11. In general, what do you find most challenging about treating and managing patients with diabetes? (Choose three of the following)